Aurobindo Pharma is acquiring the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd on a going-concern, slump-sale basis for a cash consideration of ₹325 crore. The acquisition will be carried out through Aurobindo’s wholly owned subsidiary Auro Pharma Limited and takes effect from January 1, 2026, with the consideration subject to customary working-capital adjustments, the company said in a regulatory filing.
The deal is intended to strengthen Aurobindo’s presence in India’s pain management and anti-infective segments. The acquired business comprises 23 established brands across 67 SKUs and nine pipeline products, and reported a turnover of ₹113.5 crore.
The transaction excludes inventory, intellectual property, employees and contracts. The business is currently supported by a field force of about 470 personnel and a distribution network of more than 1,600 stockists across India, which Aurobindo said will provide immediate scale and market access in the relevant segments.
Aurobindo said the transaction does not constitute a related-party deal and required no regulatory or governmental approvals. Khandelwal Laboratories’ marketed business has operated in the Indian pharmaceutical market since 1973–74 and has shown stable revenues over the past three years, reflecting maturity and brand recall in prescription markets.
Leave a Reply